186 related articles for article (PubMed ID: 21480201)
1. Comorbidity and competing risks for mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
Cancer; 2011 Oct; 117(20):4642-50. PubMed ID: 21480201
[TBL] [Abstract][Full Text] [Related]
2. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
3. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
[TBL] [Abstract][Full Text] [Related]
5. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
6. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
7. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a racially and ethnically diverse population of men with localized prostate cancer who did not undergo initial active treatment.
Slezak JM; Van Den Eeden SK; Cannavale KL; Chien GW; Jacobsen SJ; Chao CR
Cancer Med; 2020 Nov; 9(22):8530-8539. PubMed ID: 32965775
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis.
Velasquez MC; Chinea FM; Kwon D; Prakash NS; Barboza MP; Gonzalgo ML; Ritch CR; Pollack A; Parekh DJ; Punnen S
Urology; 2018 Jul; 117():108-114. PubMed ID: 29630954
[TBL] [Abstract][Full Text] [Related]
10. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
[TBL] [Abstract][Full Text] [Related]
11. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
[TBL] [Abstract][Full Text] [Related]
12. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
Lediju O; Ikuemonisan J; Salami SS; Adejoro O
J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Cooperberg MR; Broering JM; Carroll PR
J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
[TBL] [Abstract][Full Text] [Related]
14. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
[TBL] [Abstract][Full Text] [Related]
15. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.
Du XL; Fang S; Coker AL; Sanderson M; Aragaki C; Cormier JN; Xing Y; Gor BJ; Chan W
Cancer; 2006 Mar; 106(6):1276-85. PubMed ID: 16475208
[TBL] [Abstract][Full Text] [Related]
16. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
[TBL] [Abstract][Full Text] [Related]
17. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
18. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
[TBL] [Abstract][Full Text] [Related]
19. Cause of Mortality after Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-institutional Study in Korea.
Pak S; You D; Jeong IG; Lee DE; Kim SH; Joung JY; Lee KH; Hong JH; Kim CS; Ahn H
Cancer Res Treat; 2020 Oct; 52(4):1242-1250. PubMed ID: 32632083
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
Schulman AA; Howard LE; Tay KJ; Tsivian E; Sze C; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ; Polascik TJ
Cancer; 2017 Nov; 123(21):4122-4129. PubMed ID: 28662291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]